ADC Therapeutics earnings date
Want to see ADCT full AI Analyst Report?
ADC Therapeutics (ADCT) Q2 2026 Earnings Report
ADCT Q2 2026 EPS Results
- Actual EPS
- -$0.11
- Consensus EPS
- -$0.22
- Beat/Miss
- Beat by +$0.11
- One Year Ago EPS
- -$0.50
ADCT Q2 2026 Revenue Results
- Actual Revenue
- $19.25M
- Expected Revenue
- $18.89M
- Beat/Miss
- Beat by +$361.00K
- YoY Revenue Growth
- +2.17%
Earnings Announcement Details
- Quarter
- Q2 2026
- Date
- 08/13/2026
- Time
- Before Open
- Conference Call
- Thursday, August 13, 2026
ADC Therapeutics's next earnings date is estimated for March 17, 2027, based on past reporting schedules.
Q2 2026 Earnings Call Audio
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
The call presented a mixed picture: financially the company showed meaningful improvement with stable product revenues, reduced adjusted operating expenses (-22%) and a materially narrower GAAP net loss (from $56.6M to $16.6M), plus a healthy cash position and programmatic cost savings (~$10M annualized). Clinically, there are important positives — LOTIS-5 met its primary endpoint (PFS) and LOTIS-7 enrollment is complete with data the company characterizes as highly compelling. However, significant regulatory uncertainty remains because the FDA expressed substantial concerns about the LOTIS-5 benefit–risk profile and LOTIS-5 included fatal infection events (previously disclosed ~4%), creating risk to the path for full approval and timing of label/compendia actions. Operationally, cost of product sales increased materially (~188% QoQ year-over-year for the quarter) and the company recorded one-time reorganization costs tied to a ~17% headcount reduction. Given the balance of strong financial improvements and encouraging combination data versus meaningful regulatory and safety concerns, the overall tone is balanced but cautious.
The company reiterated near-term financial and development guidance: Q2 2026 ZYNLONTA net product revenue was $18.6M (vs. $18.1M in Q2 2025), cost of product sales was $2.3M in Q2 ($6.0M for the six months), GAAP operating expenses were $44.7M with non‑GAAP adjusted operating expenses of $37.2M (down 22% YoY), GAAP net loss was $16.6M (adjusted net loss $16.3M vs. $28.7M a year ago), and cash and equivalents were $219.1M (down from $231.0M at 3/31/26) supporting an expected cash runway at least into 2028; the June reorganization reduced headcount by ~17% and is expected to deliver roughly $10M of annualized cost savings. On the clinical/regulatory side, LOTIS‑5 met its primary PFS endpoint (but the FDA raised benefit‑risk concerns at a pre‑sBLA meeting and the company is assessing options), LOTIS‑7 completed enrollment of 100 patients at 150 µg/kg and an ASH abstract has been submitted, the 105‑day safety window and prophylaxis differences between trials were highlighted, the company plans ASH presentations (and publications/compendia submissions beginning in 2027), and it intends to seek breakthrough designation this year (including for MZL); since accelerated approval in 2021 ZYNLONTA has been used to treat ~5,000 U.S. patients.
- Stable Q2 Product RevenueZYNLONTA net product revenue of $18.6M in Q2 2026 versus $18.1M in Q2 2025, an increase of approximately 2.8%, and commercial performance described as broadly in line with recent quarters; ZYNLONTA monotherapy has been used to treat ~5,000 U.S. patients since accelerated approval in 2021.
- Improved Profitability and Lower Operating ExpensesGAAP net loss narrowed to $16.6M in Q2 2026 from $56.6M a year ago (an improvement of ~70.7%); non-GAAP adjusted net loss was $16.3M versus $28.7M in Q2 2025 (improvement of ~43.2%). Adjusted operating expenses were $37.2M for the quarter, down 22% year-over-year, primarily driven by lower R&D spend.
- Healthy Cash Position and RunwayCash and cash equivalents of $219.1M at quarter-end (down $11.9M from $231.0M as of March 31, 2026), providing an expected cash runway at least into 2028.
- Strategic Reorganization Driving Cost SavingsImplemented a strategic reorganization including a ~17% workforce reduction and additional operational efficiencies, estimated to generate approximately $10M of annualized cost savings while maintaining resources for key clinical, regulatory and manufacturing activities.
- LOTIS-5 Primary Endpoint Met (PFS)LOTIS-5 (Phase III ZYNLONTA + rituximab vs R-GemOx in second-line DLBCL) read out and met the primary endpoint of progression-free survival; topline data submitted to ASH and being prepared for publication and compendia submission.
- LOTIS-7 Enrollment Complete; Compelling Combination DataCompleted enrollment of 100 patients at the selected 150 µg/kg dose for LOTIS-7 (ZYNLONTA + glofitamab); abstract submitted to ASH, company characterizes the data as the most compelling combination data to date in second-line plus DLBCL, is preparing for publication and plans to pursue breakthrough designation and evaluate a potential Phase III pathway.
ADCT Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 17, 2027 | 2026 (Q4) | -0.17- | -0.04 | ― | ― |
| Nov 09, 2026 | 2026 (Q3) | -0.21-0.16 | -0.3 | 46.67% (+0.14) | |
| Aug 13, 2026 | 2026 (Q2) | -0.22-0.11 | -0.5 | 78.00% (+0.39) | |
| May 04, 2026 | 2026 (Q1) | -0.20-0.21 | -0.36 | 41.67% (+0.15) | |
| Mar 10, 2026 | 2025 (Q4) | -0.27-0.04 | -0.29 | 86.21% (+0.25) | |
| Nov 10, 2025 | 2025 (Q3) | -0.36-0.30 | -0.42 | 28.57% (+0.12) | |
| Aug 12, 2025 | 2025 (Q2) | -0.49-0.50 | -0.38 | -31.58% (-0.12) | |
| May 14, 2025 | 2025 (Q1) | -0.40-0.36 | -0.56 | 35.71% (+0.20) | |
| Mar 27, 2025 | 2024 (Q4) | -0.41-0.29 | -1.03 | 71.84% (+0.74) | |
| Nov 07, 2024 | 2024 (Q3) | -0.40-0.42 | -0.58 | 27.59% (+0.16) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


